Gene:
PRG2
proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  BMPG; MBP
PharmGKB Accession Id: PA33734

Details

Cytogenetic Location: chr11 : q12.1 - q12.1
GP mRNA Boundary: chr11 : 57154834 - 57158130
GP Gene Boundary: chr11 : 57151834 - 57168130
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

LinkOuts

Entrez Gene:
5553
OMIM:
605601
UCSC Genome Browser:
NM_002728
RefSeq RNA:
NM_002728
RefSeq Protein:
NP_002719
RefSeq DNA:
AC_000054
AC_000143
NC_000011
NT_167190
NW_001838023
NW_925106
UniProtKB:
PRG2_HUMAN (P13727)
Ensembl:
ENSG00000186652
GenAtlas:
PRG2
GeneCard:
PRG2
MutDB:
PRG2
ALFRED:
LO041423O
HuGE:
PRG2
Comparative Toxicogenomics Database:
5553
ModBase:
P13727
HumanCyc Gene:
HS05912
HGNC:
9362

Common Searches